Introduction {#s1}
============

Colorectal neoplasms (CRN) represent a wide spectrum of disease transition from precancerous colorectal polyps to colorectal cancer. In the past, disease management was principally evaluated by the effectiveness in prolonging survival and reducing disease-related complications and presentation of symptoms. The maintenance of health-related quality of life (HRQOL) following screening and treatment has driven an important new direction in research and clinical practice for patients with CRN. The assessment of HRQOL on CRN has also increased the understanding in the treatment efficiency and effectiveness, and service needs of rehabilitation[@pone.0058341-Cella1] for the interest of patients and clinicians, and subsequently facilitated the clinical decision makings[@pone.0058341-Byrne1].

There is no consensus on whether the HRQOL of CRN patients was influenced by clinical factors. For instance, there have been few attempts to characterize the associations of HRQOL with the cancer stages and the time since cancer diagnosis [@pone.0058341-Ramsey1]--[@pone.0058341-Simon1]. Evidence from the US studies did not demonstrate any associations between HRQOL and time since diagnosis in colorectal cancer patients[@pone.0058341-Ramsey1]--[@pone.0058341-Simon1]. Significant associations between HRQOL and stage at cancer diagnosis did not exist in colorectal cancer survivors[@pone.0058341-Ramsey1], [@pone.0058341-Ramsey2] but did happen in mixture of survivors and non-survivors[@pone.0058341-Simon1]. Such comparative data on the HRQOL of colorectal cancer patients with different cancer stages were limited to the US population, which might not be transferable to Asian or Chinese populations. Furthermore, no study has investigated the HRQOL of patients with colorectal polyps. The health preference score of colorectal polyp patients is contributed to the economic evaluation that informs health policy making. The cost-effectiveness analysis is one type of economic evaluation, and assesses the health outcomes in terms of quality-adjusted life years (QALYs)[@pone.0058341-National1]. The QALYs is calculated by the sum of the life years weighted by the health preference scores, anchoring on a scale from zero (death) to one (full health), of each individual staying at specific health state. Therefore, the health preference of colorectal polyp patients enables the calculation of QALYs to compare no screening against alternative colorectal cancer screening strategies in economics evaluation.

The aims of this study were: to assess the HRQOL, as measured by Short-Form 12-Item (SF-12) and 6-dimensions (SF-6D) Health Survey, of patients with different stages of CRN; and to investigate which clinical factors were related to the HRQOL of patients with CRN, after adjustment for the socio-demographic characteristics.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Ethical approval was obtained from The University of Hong Kong/ Hospital Authority Hong Kong West Cluster institutional review board (HKU/HA HKW IRB \#UW 09-391).

The study was conducted using HRQOL instruments (generic and health preference measures) to evaluate the HRQOL of patients with CRN who attended the colorectal specialist outpatient clinic at the Queen Mary Hospital in Hong Kong from October 2009 to July 2010. The inclusion criteria were that the adults patients had known stage of disease classification based on the colorectal neoplasm screening surveillance guideline[@pone.0058341-Atkin1] and the American Joint Committee on Cancer (AJCC) staging classification system for colorectal cancer[@pone.0058341-Greene1]: 1) Low-risk polyps group (patients with ≤2 adenomas or 3--4 adenomas all of which were not larger than 1 cm); 2) High-risk polyps group (patients with ≥5 adenomas or with ≥3 adenomas at least one of which was larger than 1 cm); 3) Stage I; 4) Stage II; 5) Stage III and 6) Stage IV. Those who were classified as unknown stage of disease or primary tumour site when it was unspecified in the medical record, those who was diagnosed with CRN for less than six months, those who had an expected life expectancy of less than six months, and those who had low literacy and cognitive impairment were excluded from this study. A total of 698 patients were assessed for eligibility and 600 eligible patients gave consent to enroll in the longitudinal study administering questionnaire at baseline, six months and twelve months later. The baseline data from the longitudinal study formed the basis of the current study. Five hundred and fifty-four (response rate: 79.4%) patients completed the questionnaire either by face-to-face interviews at the outpatient clinic or by telephone interviews within one month after the first contact for this research purpose at the outpatient clinic. Details of recruitment procedure have been described in authors\' previous publications[@pone.0058341-Wong1]--[@pone.0058341-Wong6].

Matched samples from an external study were used for comparison of HRQOL between CRN and the Chinese general population[@pone.0058341-Lam1]. Age-sex matched controls of 515 samples were randomly selected from a larger representative 2533 samples of Chinese general population, who were administered SF-12v2 health survey in the primary care service utilization study in 2010 by trained interviewers.

HRQOL Measures {#s2b}
--------------

This study administered the traditional Chinese version of SF-12v2 and SF-6D Health Surveys, which have been validated[@pone.0058341-Lam2]--[@pone.0058341-Lam4] and normed[@pone.0058341-Lam1] in the general Chinese population in Hong Kong.

The Chinese (HK) SF-12v2 Health Survey is a 12-item generic HRQOL measure consisted of eight subscales: Physical functioning (PF), Role physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role emotional (RE) and Mental health (MH); and two composite summary scores: Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. All subscales and summary scores were ranged from 0-100. The higher the SF-12 score, the better the HRQOL outcome. Such generic measure of HRQOL is used for measuring HRQOL of the general population including individuals living with any health condition, and subsequently enabling the head-to-head comparison between patients with CRN and population norm.

The Chinese (HK) SF-6D Health Survey, a subset of SF-12 [@pone.0058341-Brazier1] and SF-36 [@pone.0058341-Brazier2] Health Surveys, is a 6-item health preference measure ranging from 0(dead) to 1(perfect health). The SF-6D health preference scores are calculated by converting health state into a single index weighted summation from the SF-6D preference weight coefficients based on published scoring algorithm for Hong Kong population [@pone.0058341-McGhee1]. The theoretical range of SF-6D is from 0.315 (worst possible health state) to 1 (perfect health) based on Hong Kong scoring algorithm.

Patient Characteristics {#s2c}
-----------------------

Self-reported socio-demography including age, gender, marital status (Married/Non-married), educational level (No formal schooling/Primary/Secondary/Tertiary or above), household monthly income (≤HKD\$20,000/\>HKD\$20,000, pegged at an exchange rate of USD\$1 = HKD\$7.8), occupation status (Working/Non-working), smoking (Ever had/Never had) and drinking (Ever had/Never had) were collected by interviewers via telephone or face-to-face interview. Clinical characteristics including stage of colorectal neoplasm at diagnosis (Polyp: Low-risk and High-risk; Colorectal cancer: Stage I, II, III and IV), time since diagnosis (months), family history of colorectal cancer (Parents or sibling/No), primary tumour site (Colon/Rectum/Sigmoid), colorectal cancer relapse, active cancer treatment and stoma (Present/Absent) were retrieved from the electronic medical records. The later three clinical characteristics were only applicable to 380 patients diagnosed with colorectal cancer.

Statistical Analysis {#s2d}
--------------------

Socio-demographic and clinical characteristics were described overall, and by tumour stage at initial diagnosis. Chi-square or one-way analysis of variance (ANOVA) tests were used to assess the differences in categorical and continuous variables, respectively, according to the stage at diagnosis. The complete data set (n = 515), excluding 38 patients with unknown staging/primary site (n = 12) or missing values in any socio-demographic and clinical factors (n = 26), was used for further analysis of HRQOL by mean comparisons and regression analyses. HRQOL scores were determined for each stage, and the differences between stages were tested by one-way ANOVA with Tukey\'s post hoc test. The statistical power calculation was based on detecting a difference of at least 5 points in the SF-12 scores (as extrapolated from minimum clinically important difference for the SF-36 subscale scores[@pone.0058341-Hays1]) between colorectal polyp and cancer groups, with a standard deviation of 10 for the Chinese population[@pone.0058341-Lam2] and 80% power at type I error of 5%. Estimated sample size of 135 was obtained from each group, in total of 270 samples required in this study.

Normative values of SF-12v2 subscale and summary scores were extracted from 515 matched controls of 2533 samples reported in general population survey in Hong Kong[@pone.0058341-Lam1]. Mean HRQOL scores of CRN were tested against the general population norms using independent t-test.

Health preference and two SF-12v2 summary (PCS and MCS) scores were used as dependent variables in the regression analyses. Multivariate linear regression analyses were modeled to determine the effect of clinical factors on dependent variables, controlling for the effects of socio-demographic factors. No forward or backward selection procedure was applied for each regression analysis so all variables were entered in one step only. Each significant regression coefficients are presented with standard error, a 95% confidence interval, level of multicollinearity measured by tolerance and variance inflation factors (VIF). The multicollinearity occurred if the tolerance statistic was less than 0.1 or VIF was greater than 10 as a rule of thumb. The *R^2^* and adjusted *R^2^* representing the total variances of dependent variables explained were reported together with the corresponding regression analyses. Normality of residuals was examined to check the model validity by residual plot.

The SPSS Windows 20.0 program (IBM SPSS Inc., Chicago IL, USA) was used for all statistical analyses. A P-value of \<0.05 was interpreted as statistically significant in all tests.

Results {#s3}
=======

Sample Characteristics {#s3a}
----------------------

[Table 1](#pone-0058341-t001){ref-type="table"} shows the socio-demographic characteristics of the study subjects. The majority of patients were male (58%), married (75.2%), not working (75.6%), low household monthly income (83.6%), non-smokers (73.1%) and non-drinkers (72.3%). The clinical characteristics of subjects are listed in [Table 2](#pone-0058341-t002){ref-type="table"}. Ninety-three (16.8%) and 72 (13.0%) subjects were classified as low-risk and high-risk polyp group, respectively. Eighty-three (15.0%) patients were subsequently diagnosed with stage I, 101 (18.3%) with stage II, 114 (20.6%) with stage III and 82 (14.8%) with stage IV. Of those patients with colorectal cancer, 36 (6.5%) reported relapse which was more common in advanced stage than in early stage of cancer. The mean time since diagnosis was 46.7 months (SD: 55), ranged from 6 to 377 months, with a shorter time since diagnosis for Stage IV cancer. Thirty-eight point three percent of primary tumours were located in the colon, 39.8% were at the rectum and 21% were at the sigmoid colon. Most patients (86.2%) did not have stoma at the time of assessment, and most patients (76.9%) finished treatment such as adjuvant and palliative chemotherapy and/or radiotherapy.

10.1371/journal.pone.0058341.t001

###### Socio-Demographic Characteristics of Study Subjects by Colorectal Neoplasm Staging.

![](pone.0058341.t001){#pone-0058341-t001-1}

                                                                                                                                                                                 Polyp (n = 165)   Colorectal Cancer AJCC Staging (n = 381)                                              
  ------------------------------------------------------- ----------------------------------------- --------------------------------------------------------------------------- ----------------- ------------------------------------------ ----------- --------- --------- ----------- -----------
  Age (Year,mean±SD)[\*](#nt102){ref-type="table-fn"}                     63.3±11.3                  \<0.001[\*](#nt102){ref-type="table-fn"} [‡](#nt104){ref-type="table-fn"}      59.7±10.4                     63.3±12.4                   66.8±10.3   66±10.7   61.7±11   62.6±12.1   60.6±10.8
  Sex (%)                                                                                                              0.015[†](#nt103){ref-type="table-fn"}                                                                                                                             
  Male                                                                      58.1%                                                                                                     58.1%                         77.8%                       47.6%      57.4%     56.1%      56.1%       50.0%
  Female                                                                    41.9%                                                                                                     41.9%                         22.2%                       52.4%      42.6%     43.9%      43.9%       50.0%
  Education Level (%)                                                                                                                  0.379                                                                                                                                             
  No formal school                                                          10.5%                                                                                                     6.5%                           5.6%                       9.5%       15.8%     12.3%      12.2%       0.0%
  Primary                                                                   35.4%                                                                                                     28.0%                         43.1%                       40.5%      37.6%     31.6%      31.7%       62.5%
  Secondary                                                                 41.3%                                                                                                     48.4%                         38.9%                       40.5%      36.6%     42.1%      41.5%       37.5%
  Tertiary                                                                  12.8%                                                                                                     17.2%                         12.5%                       9.5%       9.9%      14.0%      14.6%       0.0%
  Marital Status (%)                                                                                                                   0.063                                                                                                                                             
  Married                                                                   75.6%                                                                                                     81.7%                         81.7%                       61.9%      75.2%     76.3%      76.8%       75.0%
  Not married                                                               24.4%                                                                                                     18.3%                         18.3%                       38.1%      24.8%     23.7%      23.2%       25.0%
  Currently Working (%)[†](#nt103){ref-type="table-fn"}                                                               \<0.001[†](#nt103){ref-type="table-fn"}                                                                                                                            
  Yes                                                                       24.4%                                                                                                     37.6%                         27.8%                       17.9%      18.8%     29.8%      11.0%       37.5%
  No                                                                        75.6%                                                                                                     62.4%                         72.2%                       82.1%      81.2%     70.2%      89.0%       62.5%
  Household Monthly Income (%)                             \<0.001[†](#nt103){ref-type="table-fn"}                                                                                                                                                                                       
  ≤HKD\$20,000                                                              83.7%                                                                                                     68.5%                         80.9%                       89.3%      92.0%     80.4%      91.0%       87.5%
  \>HKD\$20,000                                                             16.3%                                                                                                     31.5%                         19.1%                       10.7%      8.0%      19.6%      9.0%        12.5%
  Smoking (%)                                                                                                          0.042[†](#nt103){ref-type="table-fn"}                                                                                                                             
  Ever had                                                                  26.9%                                                                                                     26.9%                         36.1%                       21.4%      31.7%     16.7%      31.7%       37.5%
  Never had                                                                 73.1%                                                                                                     73.1%                         63.9%                       78.6%      68.3%     83.3%      68.3%       62.5%
  Drinking (%)                                                                                                                         0.101                                                                                                                                             
  Ever had                                                                  27.4%                                                                                                     31.2%                         30.6%                       16.7%      27.7%     23.7%      34.1%       50.0%
  Never had                                                                 72.6%                                                                                                     68.8%                         69.4%                       83.3%      72.3%     76.3%      65.9%       50.0%

Note: AJCC = American Joint Committee on Cancer

Significant difference between colorectal neoplasm staging (except unknown stage)by One-Way ANOVA

Significant difference between colorectal neoplasm staging (except unknown stage)by Chi-square Test

Significant difference between colorectal neoplasm staging (except unknown stage) by Tukey\'s Post-hoc multiple comparisons. StageI, StageII \> Low Risk

10.1371/journal.pone.0058341.t002

###### Clinical Characteristics of Study Subjects by Colorectal Neoplasm Staging.

![](pone.0058341.t002){#pone-0058341-t002-2}

                                                                                                                                                              Polyp (n = 165)   Colorectal Cancer AJCC Staging (n = 381)                                                  
  ------------------------------------------------------------------- ----------- -------------------------------------------------------------------------- ----------------- ------------------------------------------ ----------- ----------- ----------- ----------- -------------
  Primary Site (%)[‡](#nt108){ref-type="table-fn"}                                                 \<0.001[‡](#nt108){ref-type="table-fn"}                                                                                                                                
  Colon                                                                  38.3%                                                                                     55.9%                         56.9%                       20.2%       37.6%       28.9%       35.4%        25.0%
  Rectum                                                                 39.9%                                                                                     20.4%                         23.6%                       59.5%       44.6%       48.2%       36.6%        62.5%
  Sigmoid                                                                20.9%                                                                                     20.4%                         19.4%                       19.0%       17.8%       22.8%       28.0%        0.0%
  Other[\*](#nt106){ref-type="table-fn"}                                 0.9%                                                                                      3.2%                           0.0%                       1.2%        0.0%        0.0%        0.0%         12.5%
  Family History of CRC (%)                                              18.5%                                      0.241                                          21.5%                         25.7%                       15.5%       15.0%       14.0%       20.7%        37.5%
  Month of Last Diagnosis (Mean±SD)[†](#nt107){ref-type="table-fn"}    46.7±55.8   \<0.001[†](#nt107){ref-type="table-fn"} [¶](#nt110){ref-type="table-fn"}      34.4±36.0                     29.7±43.5                   68.5±65.8   66.7±63.3   44.1±55.8   25.8±28.6   131.0±131.7
  Chronic co-morbidities[‡](#nt108){ref-type="table-fn"}                                            0.001[‡](#nt108){ref-type="table-fn"}                                                                                                                                 
  Present                                                                64.8%                                                                                     71.0%                         61.1%                       76.2%       72.3%       60.5%       47.6%        50.0%
  Absent                                                                 35.2%                                                                                     29.0%                         38.9%                       23.8%       27.7%       39.5%       52.4%        50.0%
  CRC Relapsed (%)[§](#nt109){ref-type="table-fn"}                       9.4%                      \<0.001[§](#nt109){ref-type="table-fn"}                          NA                             NA                        2.4%        4.0%        5.3%        29.3%        0.0%
  Current CRC Treatment (%)[§](#nt109){ref-type="table-fn"}                                        \<0.001[§](#nt109){ref-type="table-fn"}                                                                                                                                
  No                                                                     76.9%                                                                                      NA                             NA                       100.0%       96.0%       78.9%       26.8%        80.0%
  Yes                                                                    23.1%                                                                                      NA                             NA                        0.0%        4.0%        21.1%       73.2%        20.0%
  Stoma (%)[§](#nt109){ref-type="table-fn"}                                                         0.015[§](#nt109){ref-type="table-fn"}                                                                                                                                 
  Present                                                                13.7%                                                                                      NA                             NA                        14.3%       9.9%        11.4%       18.3%        37.5%
  Absent                                                                 86.3%                                                                                      NA                             NA                        85.7%       90.1%       88.6%       81.7%        25.0%

Note: AJCC = American Joint Committee on Cancer

Other included those who had unknown or double primary site.

Significant difference between colorectal neoplasm staging (except unknown stage) by One-Way ANOVA

Significant difference between colorectal neoplasm staging (except unknown stage) by Chi-square Test

Significant difference between colorectal cancer staging (except unknown stage) by Chi-square Test

Significant difference between colorectal neoplasm staging (except unknown stage) by Tukey\'s Post-hoc multiple comparisons. StageI, StageII \> Low Risk, High Risk, StageIII, StageIV

Comparisons among Stage of Disease and with General Population {#s3b}
--------------------------------------------------------------

[Table 3](#pone-0058341-t003){ref-type="table"} and [Figure 1](#pone-0058341-g001){ref-type="fig"} presents the subscale and overall mean SF-12 subscale scores for CRN patients compared with general population. CRN patients reported statistically worse scores for the physical aspects of HRQOL (PF, RP and PCS) compared with general population. For other aspects of HRQOL, CRN patients reported statistically better scores for BP, GH, VT, RE, MH and MCS than general population.

![Mean SF-12v2 scores of patients with colorectal neoplasms compared with age-sex matched controls from the Chinese general population.](pone.0058341.g001){#pone-0058341-g001}

10.1371/journal.pone.0058341.t003

###### Descriptive Statistics (Mean and SD) of HRQOL Scores for Patients with Colorectal Neoplasms Compared with Age-Sex Matched Controls from Chinese General Population.
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                 Age-Sex Matched Controls (N = 515)   Colorectal Neoplasms (N = 515)   Difference (Matched Controls - Colorectal Neoplasms)   Difference (Matched Controls - Colorectal polyp)   Difference (Matched Controls - Colorectal cancer)                                                                                                                                                                         
  ------------- ------------------------------------ -------------------------------- ------------------------------------------------------ -------------------------------------------------- --------------------------------------------------- ----------------- ------------------------------------------ ------------- ----------------- ------------------------------------------ ------------ ----------------- ------------------------------------------
  **SF-12v2**                                                                                                                                                                                                                                                                                                                                                                                                              
  PF                         83.9±25.1                         (81.8,86.1)                                  78.5±29.6                                           (76.0,81.1)                                          5.39±1.71                         (2.04,8.74)      0.002[\*](#nt114){ref-type="table-fn"}    −1.46±2.37     (−6.10,3.19)                      0.538                     7.11±1.91     (3.37,10.85)     \<0.001[\*](#nt114){ref-type="table-fn"}
  RP                         79.4±25.3                         (77.2,81.6)                                  76.2±27.6                                           (73.8,78.6)                                          3.20±1.65                        (−0.04,6.44)                      0.053                     −5.07±2.34    (−9.66, −0.48)     0.031[\*](#nt114){ref-type="table-fn"}    5.04±1.87      (1.37,8.71)      0.007[\*](#nt114){ref-type="table-fn"}
  BP                         78.8±25.9                         (76.6,81.1)                                  86.7±22.9                                           (84.8,88.7)                                         −7.91±1.52                       (−10.90, −4.93)   \<0.001[\*](#nt114){ref-type="table-fn"}   −12.49±2.32   (−17.04, −7.93)   \<0.001[\*](#nt114){ref-type="table-fn"}   −7.56±1.75   (−10.99, −4.12)   \<0.001[\*](#nt114){ref-type="table-fn"}
  GH                         46.2±28.6                         (43.7,48.7)                                  52.3±25.8                                           (50.1,54.6)                                         −6.16±1.70                       (−9.49, −2.83)    \<0.001[\*](#nt114){ref-type="table-fn"}   −7.87±2.49    (−12.75, −2.98)    0.002[\*](#nt114){ref-type="table-fn"}    −6.97±1.86   (−10.63, −3.32)   \<0.001[\*](#nt114){ref-type="table-fn"}
  VT                         61.4±28.3                         (58.9,63.8)                                  67.2±19.7                                           (65.5,68.9)                                         −5.87±1.52                       (−8.86, −2.89)    \<0.001[\*](#nt114){ref-type="table-fn"}   −10.68±2.46   (−15.51, −5.86)   \<0.001[\*](#nt114){ref-type="table-fn"}   −6.02±1.74   (−9.42, −2.61)    \<0.001[\*](#nt114){ref-type="table-fn"}
  SF                         82.4±25.1                         (80.2,84.5)                                  81.5±28.6                                           (79.0,83.9)                                          0.92±1.67                        (−2.36,4.21)                      0.582                     −6.90±2.33    (−11.47, −2.33)    0.003[\*](#nt114){ref-type="table-fn"}    3.64±1.90     (−0.08,7.36)                      0.055
  RE                         79.9±22.6                         (77.9,81.9)                                  89.3±19.4                                           (87.6,91.0)                                         −9.37±1.31                       (−11.94, −6.79)   \<0.001[\*](#nt114){ref-type="table-fn"}   −12.78±1.98   (−16.68, −8.88)   \<0.001[\*](#nt114){ref-type="table-fn"}   −9.20±1.50   (−12.15, −6.25)   \<0.001[\*](#nt114){ref-type="table-fn"}
  MH                         70.9±19.3                         (69.3,72.6)                                  79.6±15.6                                           (78.3,81.0)                                         −8.69±1.09                       (−10.84, −6.54)   \<0.001[\*](#nt114){ref-type="table-fn"}   −9.37±1.66    (−12.62, −6.12)   \<0.001[\*](#nt114){ref-type="table-fn"}   −8.40±1.23   (−10.81, −5.99)   \<0.001[\*](#nt114){ref-type="table-fn"}
  PCS                        47.0±11.5                         (46.0,48.0)                                  46.9±10.6                                           (46.0,47.8)                                          0.10±0.69                        (−1.25,1.45)                      0.885                     −2.76±1.03    (−4.79, −0.73)     0.002[\*](#nt114){ref-type="table-fn"}    0.70±0.78     (−0.84,2.23)                      0.369
  MCS                        50.5±10.4                         (49.6,51.4)                                   57.2±8.0                                           (56.5,57.9)                                         −6.66±0.58                       (−7.80, −5.53)    \<0.001[\*](#nt114){ref-type="table-fn"}   −7.48±0.89    (−9.22, −5.74)    \<0.001[\*](#nt114){ref-type="table-fn"}   −6.52±0.64   (−7.79, −5.26)    \<0.001[\*](#nt114){ref-type="table-fn"}

Note:

SF-12 subscales: PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH = mental health; PCS = Physical Composite Summary; MCS = Mental Composite Summary

Higher score represents a higher level of functioning or better quality of life

Significant difference between samples from our study and general population surveys by independent t-test

Mean HRQOL scores in relation to stage of disease at diagnosis are presented in [Table 4](#pone-0058341-t004){ref-type="table"}, [Figure 2](#pone-0058341-g002){ref-type="fig"} and [Figure 3](#pone-0058341-g003){ref-type="fig"}. Patients with metastatic colorectal cancer had the lowest HRQOL, with significantly lower HRQOL scores than low-risk polyp and early stages of colorectal cancer. There was an unexpected increase trend in the MCS and health preference scores from early to late stages of cancer although the differences were not statistically significant. Health preference scores of stage II patients were generally higher than those of patients with late stages of cancer.

![Mean SF-12v2 summary scores by stage of disease.](pone.0058341.g002){#pone-0058341-g002}

![Mean SF-6D health preference score by stage of disease.](pone.0058341.g003){#pone-0058341-g003}

10.1371/journal.pone.0058341.t004

###### Descriptive Statistics (Mean and SD) of Questionnaire Scores at Baseline by CRN Groups
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                                    Colorectal Neoplasm Staging                                                                   
  ------------------- ------------ ----------------------------- ------------ ------------ ------------ ------------ ------------ --------------------
  **SF-12**                                                                                                                       
  PF                   78.5±29.6             85.0±24.8            84.1±25.8    77.2±30.3    85.1±25.2    75.7±30.7    63.5±34.5        1,2,3,4\>6
  RP                   76.2±27.6             85.3±21.8            80.9±22.0    76.7±28.8    82.8±23.5    74.1±26.4    55.9±32.8    1\>5; 1,2,3,4,5\>6
  BP                   86.7±22.9             88.2±20.6            92.8±16.3    87.2±19.9    90.7±20.4    83.5±25.5    78.9±29.2          2,4\>6
  GH                   52.3±25.8             55.4±24.6            49.9±22.6    53.6±27.1    57.9±24.6    52.0±26.0    43.0±27.7          1,4\>6
  VT                   67.2±19.7             71.2±17.9            69.7±18.9    66.6±22.5    72.2±16.7    65.1±18.0    57.9±22.1         1,2,4\>6
  SF                   81.5±28.6             92.1±18.2            84.8±26.3    81.3±27.4    88.6±24.0    78.7±29.4    61.5±34.7    1\>5; 1,2,3,4,5\>6
  RE                   89.3±19.4             91.9±16.2            91.7±14.8    91.6±17.8    91.4±18.7    88.4±19.4    80.3±25.7        1,2,3,4\>6
  MH                   79.6±15.6             80.4±14.0            80.1±13.0    81.4±16.3    80.8±15.3    78.9±15.8    75.8±18.5   
  PCS                  46.9±10.6             49.7±9.0              49.0±8.7    46.5±10.7     49.9±8.4    45.8±10.9    40.4±12.5       1,2,3,4,5\>6
  MCS                   57.2±8.0             58.3±6.7              57.4±7.7     58.1±7.4     58.0±7.3     56.9±7.9    54.3±10.2         1,3,4\>6
  **SF-6D**                                                                                                                       
  Health Preference    0.825±0.14           0.871±0.12            0.832±0.12   0.831±0.14   0.858±0.12   0.817±0.13   0.732±0.15      1,2,3,4,5\>6

Note:

FACT-C subscales: PWB = physical well-being; SWB = social well-being; EWB = emotional well-being; FWB = functional well-being; CCS = colorectal cancer subscale; TOI = trial outcome index;

SF-12 subscales: PF = physical functioning; RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = role emotional; MH = mental health; PCS = Physical Composite Summary; MCS = Mental Composite Summary

Higher score represents a higher level of functioning or better quality of life

Significant difference between six colorectal neoplasm groups by Tukey\'s Post-hoc multiple comparisons. 1:Low Risk; 2:High Risk; 3:StageI; 4:StageII; 5:StageIII; 6:StageIV;

Correlates of Generic and Health Preference Measures of HRQOL {#s3c}
-------------------------------------------------------------

[Table 5](#pone-0058341-t005){ref-type="table"} demonstrates the socio-demographic and clinical factors associated with generic and health preference measures of HRQOL by multiple linear regression models. Stage of disease at diagnosis was the clinical determinants for HRQOL outcomes with statistical significance in each indicator level of stage. Clinical and socio-demographic factors explained 11.9% (8.3%), 10.2% (6.6%) and 14.8% (11.3%) of the total variation, as determined by *R^2^* (adjusted *R^2^*), in PCS, MCS and health preference scores of patients with CRN, respectively. The multicollinearity did not occur in our regression models because the tolerance statistic and VIF were ≥0.1 and ≤10, respectively, for all significant regression coefficients. Health preference score was poorer in patients with rectal neoplasm (−0.0302, 95% CI: −0.0597 to −0.0008) but better in longer diagnosis duration (0.0002, 95% CI: 0.0000 to 0.0005). MCS and health preference scores were greater in patients who were male and older. Rectal neoplasm patients reported worse PCS scores (2.81, 95% CI: −5.14 to −0.47) compared to sigmoid neoplasm patients. HRQOL scores did not differ significantly by the presence of chronic co-morbidities and family history of colorectal cancer.

10.1371/journal.pone.0058341.t005

###### Clinical and Socio-demographic Factors Associated with HRQOL Scores in CRN Patients (n = 515) by Multiple Linear Regression.

![](pone.0058341.t005){#pone-0058341-t005-5}

                                                          SF-12 PCS                  SF-12 MCS       SF-6D                      Tolerance                  VIF                                                                                                    
  ---------------------------------------- ---------------------------------------- ----------- ---------------- ---------------------------------------- ------ --------------- ------------------------------------------ -------- -------------------- ------- -------
  Constant                                  [\*](#nt122){ref-type="table-fn"}39.81     3.78      (32.41,47.21)    [\*](#nt122){ref-type="table-fn"}45.40   2.87   (39.78,51.01)   [\*](#nt122){ref-type="table-fn"}0.6436    0.0478    (0.5500,0.7372)            
  *Clinical Factors*                                                                                                                                                                                                                                              
  Colorectal Neoplasm Staging (Stage IV)                                                                                                                                                                                                                          
   Low-risk Polyp                           [\*](#nt122){ref-type="table-fn"}8.44      1.66       (5.19,11.69)    [\*](#nt122){ref-type="table-fn"}3.82    1.26    (1.35,6.28)    [\*](#nt122){ref-type="table-fn"}0.1248    0.0210    (0.0837,0.1659)     0.506   1.975
   High-risk Polyp                          [\*](#nt122){ref-type="table-fn"}8.02      1.73       (4.63,11.42)                     2.14                    1.31   (−0.44,4.71)    [\*](#nt122){ref-type="table-fn"}0.0841    0.0219    (0.0411,0.1270)     0.572   1.748
   Stage I                                  [\*](#nt122){ref-type="table-fn"}5.49      1.70       (2.15,8.83)     [\*](#nt122){ref-type="table-fn"}3.74    1.29    (1.21,6.28)    [\*](#nt122){ref-type="table-fn"}0.0903    0.0215    (0.0481,0.1326)     0.504   1.986
   Stage II                                 [\*](#nt122){ref-type="table-fn"}8.91      1.59       (5.80,12.02)    [\*](#nt122){ref-type="table-fn"}3.10    1.20    (0.74,5.46)    [\*](#nt122){ref-type="table-fn"}0.1143    0.0201    (0.0749,0.1537)     0.490   2.040
   Stage III                                [\*](#nt122){ref-type="table-fn"}4.89      1.54       (1.88,7.91)     [\*](#nt122){ref-type="table-fn"}2.61    1.17    (0.33,4.90)    [\*](#nt122){ref-type="table-fn"}0.0760    0.0195    (0.0379,0.1142)     0.486   2.058
  Months Since Diagnosis†                                    0.02                      0.01       (0.00,0.03)                      0.00                    0.01   (−0.01,0.01)    [\*](#nt122){ref-type="table-fn"}0.0002    0.0001    (0.0000,0.0005)     0.868   1.152
  Primary (Sigmoid)                                                                                                                                                                                                                                               
   Colon                                                    −1.74                      1.20       (−4.10,0.62)                     0.01                    0.91   (−1.78,1.80)                    −0.0073                    0.0152    (−0.0372,0.0225)    0.564   1.773
   Rectum                                   [\*](#nt122){ref-type="table-fn"}−2.81     1.19      (−5.14, −0.47)                   −1.15                    0.90   (−2.91,0.62)    [\*](#nt122){ref-type="table-fn"}−0.0302   0.0150   (−0.0597, −0.0008)   0.561   1.783
  Family History of CRC                                      0.36                      1.16       (−1.91,2.62)                    −0.36                    0.88   (−2.08,1.36)                     0.0047                    0.0146    (−0.0240,0.0333)    0.947   1.056
  Chronic co-morbidities                                    −0.18                      1.03       (−2.20,1.84)                    −0.30                    0.78   (−1.84,1.23)                    −0.0090                    0.0130    (−0.0346,0.0165)    0.797   1.255
  *Socio-demographic Factors*                                                                                                                                                                                                                                     
  Male                                                       0.42                      1.05       (−1.64,2.49)    [\*](#nt122){ref-type="table-fn"}2.06    0.80    (0.49,3.62)    [\*](#nt122){ref-type="table-fn"}0.0297    0.0133    (0.0036,0.0557)     0.714   1.401
  Age†                                                       0.04                      0.05       (−0.06,0.14)    [\*](#nt122){ref-type="table-fn"}0.16    0.04    (0.08,0.24)    [\*](#nt122){ref-type="table-fn"}0.0014    0.0006    (0.0001,0.0027)     0.568   1.761
  Education (Tertiary)                                                                                                                                                                                                                                            
   No Formal Schooling                                      −0.33                      2.01       (−4.28,3.61)                     0.09                    1.53   (−2.90,3.08)                     0.0026                    0.0254    (−0.0472,0.0525)    0.497   2.012
   Primary                                                   0.40                      1.59       (−2.72,3.52)                    −1.20                    1.21   (−3.57,1.17)                     0.0056                    0.0201    (−0.0339,0.0450)    0.331   3.019
   Secondary                                                −0.43                      1.47       (−3.31,2.44)                    −0.23                    1.11   (−2.40,1.95)                     0.0032                    0.0185    (−0.0331,0.0395)    0.369   2.709
  Married                                                    0.04                      1.07       (−2.06,2.15)                    −0.09                    0.82   (−1.68,1.51)                     0.0046                    0.0136    (−0.0221,0.0312)    0.904   1.106
  Currently Working                                          1.55                      1.29       (−0.97,4.08)                     0.77                    0.98   (−1.15,2.68)                     0.0311                    0.0163    (−0.0008,0.0630)    0.637   1.570
  Household Monthly Income ≤HK\$20000                       −1.89                      1.43       (−4.69,0.92)                    −0.65                    1.08   (−2.78,1.47)                    −0.0213                    0.0181    (−0.0568,0.0141)    0.688   1.453
  Ever Smoking                                               0.75                      1.19       (−1.59,3.09)                    −1.11                    0.91   (−2.89,0.66)                     0.0209                    0.0151    (−0.0087,0.0505)    0.686   1.458
  Ever Drinking                                              0.26                      1.18       (−2.05,2.57)                     0.23                    0.89   (−1.52,1.98)                    −0.0095                    0.0149    (−0.0386,0.0197)    0.706   1.417
  R^2^                                                      11.9%                                                                 10.2%                                                            14.8%                                                          
  Adjusted R^2^                                              8.3%                                                                  6.6%                                                            11.3%                                                          

Note: CRN = Colorectal Neoplasms; CRC = Colorectal Cancer; VIF = Variance Inflation Factors; PCS = Physical Composite Summary; MCS = Mental Composite Summary

() Variable in brackets is the reference category for independent variables

Significant independent variables (p\<0.05) on HRQOL by multivariate linear regression;† HRQOL scores change in coefficient for each unit increase in independent variable.

Discussion {#s4}
==========

This is the first study, to our knowledge, to compare the HRQOL in Chinese patients with CRN with the general population and to highlight the HRQOL differences among stage of disease at the time of diagnosis. CRN patients reported similar physical-related HRQOL and better mental-related HRQOL compared to matched controls from the Chinese general population. Among all socio-demographic and clinical factors, stage of disease at diagnosis was the only significant and influential factor correlated to generic and health preference scores of HRQOL outcomes. Compared to sigmoid neoplasms, rectal neoplasms were associated with poorer outcomes on generic and health preference although mental-related HRQOL showed a non-significant decline. The effect of time since diagnosis on HRQOL was positive but significant for health preference scores only. Socio-demographic factors such as educational level, marital status, working status, household income, smoking status and drinking status were not significant correlates of HRQOL outcomes.

Many studies collected the HRQOL of a sample of CRC patients and compared with normative values published in population-based data. Amongst comparative studies, only one UK study utilized the SF-12 scores comparisons of general population norms with colorectal cancer patients after surgery[@pone.0058341-Wilson1]. Those cancer survivors had lower PCS score and higher MCS score compared to the UK population with an age interval of 65--74 years. Our study found the signs of difference between groups were consistent with the UK study, regardless of physical-related and mental-related HRQOL. However, the present study did not detect significant differences in physical-related HRQOL between groups, indicating the CRN patients were not associated with significant impairment of the physical-related HRQOL in Chinese population.

HRQOL decreased linearly with more severe stages of colorectal cancer, providing consistent evidence as reported in European and Australian studies[@pone.0058341-Sharma1]--[@pone.0058341-Rinaldis1]. On the other hand, based on the data presented in the current study, patients with stage II colorectal cancer reported better HRQOL than those with stage I colorectal cancer but worse HRQOL than those with advanced stage of cancer. These particular findings were in line with two previous US studies which assessed the health preference scores using the Health Utility Index Mark III (HUI3) among colorectal cancer patients with 13--24 months from diagnosis[@pone.0058341-Ramsey1]; and assessed the vitality subscale using the SF-36 Health Survey among long term colorectal cancer survivors who were at least five years from initial diagnosis[@pone.0058341-Ramsey2]. However, no evidence from the US studies [@pone.0058341-Ramsey1], [@pone.0058341-Ramsey2], [@pone.0058341-TrenthamDietz1]--[@pone.0058341-Ristvedt1] had a tendency of relationship between stage at diagnosis and HRQOL. One of the possible reasons was, in turn, the change in the perception (or re-conceptualization) of HRQOL so called response shift [@pone.0058341-Sprangers1], as a result of either clinical interventions or self-coping with colorectal cancer[@pone.0058341-Bernhard1].

The present study suggested that factors associated with HRQOL scores were different from those related to health preference scores. Significant improvements in patients\' HRQOL scores, but surprising not in health preference scores, were found with longer time since CRN diagnosis. Ramsey et al. [@pone.0058341-Ramsey1] addressed that strong and negative impact on health preference measure was experienced within the first two years of colorectal cancer diagnosis but the uniform improvement over two years was found. There was no significant change detected among different time periods in patients who were at least 13 months [@pone.0058341-Ramsey1] and at least 60 months (or 5 years) [@pone.0058341-Ramsey2] from initial diagnosis of colorectal cancer. However, longer time since diagnosis was associated with better health preference measure. It is postulated that the inconsistent findings between previous and current studies were in part due to the differences in the measurement type of 'Time from Diagnosis'. Those studies conducted data analysis by partitioning 'Time from Diagnosis' into several time periods as an ordinal factor.

Physical aspect of HRQOL and health preference scores reported by rectal neoplasm patients were significantly worse than those scores reported by patients with other primary tumour locations. It is possible that the impact of tumour site on HRQOL was primarily due to the effects of treatment modalities. Rectal neoplasm may be undertaken by the radiotherapy before or after surgery but colon neoplasm does not. Most of the patients with rectal cancer underwent resection with the installation of stoma [@pone.0058341-Wong2], leading to the burden of daily activities and living. Having stoma was significantly associated with lower HRQOL scores in Western populations (e.g. France [@pone.0058341-Rauch1], US [@pone.0058341-Liu1], [@pone.0058341-Krouse1] and Denmark[@pone.0058341-Ross1]). A Japanese study [@pone.0058341-Shiroiwa1] showed that patients with stoma had worse health preference scores derived using direct valuation techniques. No significant HRQOL difference among patients with stoma was found in our Chinese population, which paralleled with the most recent study on colorectal cancer survivors[@pone.0058341-Hornbrook1]. One interpretation of our findings was that HRQOL of patients with stoma was improved by the growing medical advances in surgical resection and follow-up stoma care services, and further reduced the risk of stoma complications and identified better adaptation and coping strategy to live with stoma [@pone.0058341-deGouveiaSantos1].

Limitations {#s4a}
-----------

Several shortcomings were noted. First, sampling bias regarding the use of convenience sampling from a specialist outpatient clinic of one regional hospital in Hong Kong may limit the generalizability of results to CRN patients in Chinese and other populations. A high proportion of unemployed, low household income, or low educated patients in this sample has raised caution with interpretation and extrapolation the findings to other populations with different patient characteristics. Moreover, possible sampling issue related to non-response bias was addressed in a previous study because subjects who did not respond in follow-up assessment had a significant inferior HRQOL at the initial survey than those who did[@pone.0058341-Yost1]; healthier patients seemed less likely to be dropped from the follow-up assessments. In such circumstance, non-response bias led by the dropout of consented subjects with inferior HRQOL may potentially underestimate the HRQOL in this study. Second, *R^2^* (or adjusted *R^2^*) did not exceed 20% in linear regression analyses, suggesting that only a small proportion of the variance in HRQOL outcomes could be explained by the independent variables. The inclusion of variables related to adiposity and healthy lifestyle behaviours such as consumption of fruit and vegetable, and regular exercise, was an attempt to increase the understanding of underlying factors associated with HRQOL. Finally, as a cross-sectional study, our results can only give clues on casual and effect relationships but not the definitive relationships between independent variables and HRQOL.

Conclusion {#s5}
==========

Stage of disease at initial diagnosis was the most significant clinical correlate for all HRQOL outcomes in patients with CRN. Specificity, those CRN patients who simultaneously had rectum as primary tumor site and severe stage of disease at diagnosis, indicated suboptimal HRQOL in relation to physical aspect of HRQOL and health preference scores. Based on available Chinese data on health preference scores, the QALYs is estimated for the cost-effectiveness analysis of CRN-related interventions in economics evaluation.
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